Atara Biotherapeutics, Inc. (ATRA): R&D Expense
$37.45M
Year ended 2025-12-31
$4.21M
Trailing 12 months to 2026-06-30
-48.4%
3-year compound annual growth
-31.3%
5-year compound annual growth
-1.1%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $37.45M | -75.3% | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | $151.48M | -32.6% | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | $224.78M | -17.5% | 2025-03-07, From 2023-01-01 |
| 2022-12-31 | $272.53M | -3.4% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $282.00M | +15.3% | 2023-02-08, From 2021-01-01 |
| 2020-12-31 | $244.65M | +13.2% | 2023-02-08, From 2020-01-01 |
| 2019-12-31 | $216.10M | +29.0% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $167.46M | +106.2% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $81.21M | +43.7% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $56.51M | +35.8% | 2019-02-26, From 2016-01-01 |
| 2015-12-31 | $41.62M | +169.4% | 2018-02-27, From 2015-01-01 |
| 2014-12-31 | $15.45M | n/a | 2017-03-09, From 2014-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $37.45M | -75.3% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $141.50M | +16.4% |
| Agenus Inc (AGEN) | 2025-12-31 | $79.34M | -49.0% |
| ImmunityBio, Inc. (IBRX) | 2024-12-31 | $190.14M | -18.2% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $95.67M | -10.8% |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $409.62M | +11.4% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $166.42M | -34.0% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $243.77M | -42.5% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $228.30M | +9.5% |
Compare ATRA, GLUE, AGEN, IBRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗